Synbiotic compositions for enhancing and restoring gut epithelial barrier
Patent Information
- Application Number
- MYPI2025005726
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-23
- Filing Date
- 2024-03-20
- Publication Date
- 2024-09-23
Smart Images

Figure PI2025005726_DRAWING_001 
Figure PI2025005726_DRAWING_002 
Figure PI2025005726_DRAWING_003
Abstract
Description
SYNBIOTIC COMPOSITIONS FOR ENHANCING AND RESTORING GUT EPITHELIAL BARRIER
[0001] RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 454,243, filed March 23, 2023, the contents of which are hereby incorporated by reference in the entirety for all purposes.BACKGROUND OF THE INVENTION
[0003] The gut epithelial barrier is an integral part of the intestinal barrier, which plays a central role in health and disease by facilitating nutrient absorption and preventing the entry of pathogens. Mounting evidence now suggests that intestinal barrier is compromised in digestive disorders including colorectal cancer and inflammatory bowel disease. The gut microbiome, having strong interaction with the gut epithelium, regulate the integrity and function of the intestinal barrier. A perturbed gut microbiota may disrupt the intestinal barrier while certain beneficial microorganisms may help restore it. It is however unclear which specific microorganisms have such effect, hindering efforts to formulate compositions effective for treating these conditions.
[0004] Accordingly, there exists an urgent need for new and meaningful methods to facilitate the maintenance of a healthy gut epithelial barrier as well as the prevention and treatment of gastrointestinal disorders involving a leaky gut barrier. The purpose of this study is to identify gut microbial species and specific combinations thereof that can provide the beneficial effects of enhancing or restoring the integrity of gut barrier among susceptible individuals. Direct supplementation of these beneficial gut microbial species is a potentially effective means to maintain and improve a person’s gut health, thus treating pertinent gastrointestinal diseases and preventing the development of such diseases. The present invention fulfills this and other related needs by identifying beneficial gut microorganisms in an effort to formulate new compositions and devise new methods that are effective for enhancing or restoring gut barrier among individuals suffering from disorders involving compromised gut barrier.
[0005] BRIEF SUMMARY OF THE INVENTION
[0006] The present inventors discovered in their studies the certain gut microbial species can help maintain healthy gut epithelial barrier and therefore can help enhance or restore the gut barrier especially in individuals suffering from or at risk of developing diseases and conditions involving leaky gut barrier (e.g., various intestinal disorders) , thus provide an important utility in the prevention and treatment of pathologies caused by compromised gut epithelial barrier.
[0007] In a first aspect, the present invention provides a composition that is useful for maintaining healthy gut epithelial barrier and / or for restoring / enhancing gut epithelial barrier in individuals in need thereof. The composition comprises an effective amount of (1) Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus; and (2) a physiologically acceptable excipient. In some embodiments, Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus are present in the composition in the colony-forming unit (CFU) ratio of about (1-2) : about 1 : about (0.5-1.5) : about (0-2) . In some embodiments, the composition comprises one or more strains of each of Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus. In some embodiments, the composition comprises a total of about 106 to about 1012 CFU of Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus. In some embodiments, the composition may further comprise inulin, galactooligosaccharide, and polydextrose. In some embodiments, the composition contains prebiotics inulin, galactooligosaccharide, and polydextrose in the weight ratio of about (2-5) : about 1 : about (2-4) . In some embodiments, the composition may further include tara gum. For example, inulin, galactooligosaccharide, polydextrose, and tara gum are present in the composition in the weight ratio of about (2-5) : about 1 : about (2-4) : about (0-0.5) . In some embodiments, the composition comprises a total amount of about 0.1 to about 8 grams of inulin, galactooligosaccharide, polydextrose, and tara gum. In some embodiments, the composition is formulated for oral ingestion, e.g., in the form of a food or beverage item. In some embodiments, the composition is formulated in subdoses for administration two, three, four, or more times per day with one subdose each time.
[0008] In the second aspect, the present invention provides a method for enhancing or restoring the gut epithelial barrier function or for treating a condition involving a leaky gut epithelium barrier in a subject in need thereof by administering to the subject an effective amount of the composition described herein: a composition comprises an effective amount of (1) Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus; and (2) a physiologically acceptable excipient. In some embodiments, the administering step comprises administering to the subject one composition comprising Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus. In some embodiments, the subject is also administered inulin, galactooligosaccharide, and polydextrose, optionally further administered tara gum. In some embodiments, the administering step comprises administering to the subject a first composition comprising Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus, and administering to the subject a second composition comprising inulin, galactooligosaccharide, polydextrose, and optionally tara gum. In some embodiments, the administering step comprises oral ingestion of the composition (s) . In some embodiments, the administering step comprises oral ingestion prior to or with food intake. In some embodiments, the subject has been diagnosed with a condition or disease involving or indicative of leaky gut or has been deemed to have a heighten risk of developing such a condition or disease, for example, has been diagnosed with an intestinal disease or is at risk for an intestinal disease, such as colorectal cancer, inflammatory bowel disease, Celiac disease, Crohn’s disease, ulcerative colitis, irritable bowel syndrome, and the like.
[0009] In a related aspect, the present invention provides a novel use of a composition for maintaining a healthy gut epithelial barrier or for treating a condition involving leaky gut barrier in a subject. Prepared for this use is a composition comprises an effective amount of (1) Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus; and (2) a physiologically acceptable excipient. In some embodiments, the subject is administered one composition comprising Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus. In some embodiments, the subject is also administered galactooligosaccharide, inulin, and polydextrose, optionally further administered tara gum. In some embodiments, the subject is administered a first composition comprising the beneficial bacteria (Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus) and is administered a second composition comprising inulin, galactooligosaccharide, polydextrose, and optionally tara gum. In some embodiments, the composition (s) are formulated for oral ingestion. In some embodiments, the oral ingestion is prior to or with food intake. In some embodiments, the subject has been diagnosed with a condition or disease involving or indicative of leaky gut or deemed at a heighten risk of developing such a condition or disease, for example, has been diagnosed with an intestinal disease or is at risk for an intestinal disease, such as colorectal cancer, inflammatory bowel disease, Celiac disease, Crohn’s disease, ulcerative colitis, irritable bowel syndrome, and the like.
[0010] In a third aspect, the present invention provides a kit for maintaining, enhancing, or restoring gut epithelial barrier or for treating a condition involving leady gut barrier in a subject. The kit includes a plurality of containers, containing a plurality of compositions, which together provide an effective amount of the beneficial bacteria of Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus. The plurality of compositions may also include an effective amount of prebiotics inulin, galactooligosaccharide, polydextrose, optionally further including tara gum. In some embodiments, the kit includes two containers containing a first composition, which comprises an effective amount of the beneficial bacteria (Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus) and a second composition, which comprises an effective amount of inulin, galactooligosaccharide, polydextrose, and optionally tara gum. In some embodiments, each of the compositions is in the form of a powder, liquid, paste, cream, tablet, or capsule. In some embodiments, the kit may also include instructional materials for the user for the proper use of the kit, e.g., patients who have been diagnosed with a condition or disease involving or indicative of leaky gut or have been deemed at a heighten risk of developing such a condition or disease, for example, an intestinal disease such as colorectal cancer, inflammatory bowel disease, Celiac disease, Crohn’s disease, ulcerative colitis, irritable bowel syndrome, and the like.BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1. Relative expression level of IL-6 mRNA by Caco-2 cells with or without LPS and SMT04 treatment. Figure 1A: Caco-2 cells were treated with SMT04 (SMT04) and compared to those without treatment (Blank) . Error bars indicate SD. *P<0.05; **P<0.01; ***P<0.001, Unpaired t test. Figure 1B: Caco-2 cells were treated with LPS (LPS) , concurrently treated with LPS and SMT04 (LPS+SMT04) or subjected to no treatment (Blank) . Transcription levels of IL-6 were detected with real-time PCR following the manual’s instructions. Each bar indicates the mean relative expression of IL-6 (fold change) . Error bars indicate SD. *P<0.05; **P<0.01; ***P<0.001, One way ANOVA.
[0012] Figure 2. Effect of SMT04 on colonic epithelial tight junction protein. Expression of occludin (A) zonula occludens 1 (B) , and claudin 1 (C) by Caco-2 cells were compared between treatment with LPS (LPS) , concurrent treatment with LPS and SMT04 (LPS+SMT04) and without any treatment (Blank) . Each bar indicates the mean relative expression of the corresponding tight junction protein (fold change) . Error bars indicate SD. *P<0.05; **P<0.01; ***P<0.001, One way ANOVA. OCLN –occluding; ZO1 -zonula occludens 1 (ZO1) .
[0013] Figure 3. Effect of SMT04 on gut epithelial permeability evaluated by FITC-dextran permeability assay. Fluorescence intensity of FITC-conjugated dextran transferring from the upper to the lower chambers of Transwell was measured in each lower chamber after treatment with LPS alone (LPS) , concurrent treatment with LPS and SMT04 (LPS+SMT04) , SMT04 alone (SMT04) and without any treatment (Blank) . Each bar indicates the mean relative FITC fluorescence intensity. Error bars indicate SD. *P<0.05; **P<0.01; ***P<0.001, One way ANOVA.
[0014] DEFINITIONS
[0015] As used herein, the term “gut epithelial barrier, ” “intestinal epithelial barrier, ” or simply “gut barrier” refers to the single cell layer that forms the luminal surface or inside lining of both the small and large intestine (colon) of the gastrointestinal tract. Composed of simple columnar epithelial cells, a healthy gut epithelial barrier serves two main functions: absorbing useful substance into the body and restricting the entry of harmful substance. Factors such as stress, unhealthy diet, drug / alcohol consumption, or use of antibiotics, however, may compromise the integrity of gut barrier, resulting in gut barrier dysfunction as manifested in a variety of diseases and disorders involving or indicative of “leaky gut” as a causal or exacerbating factor, which include intestinal diseases, such as food allergies, irritable bowel syndrome, inflammatory bowel disease, celiac disease, Crohn’s Disease, ulcerative colitis, small intestinal barrier overgrowth, and abnormal colorectal growth (e.g., polyps, adenoma, or cancer) , as well as extra-intestinal diseases such as brain / mental disorders (e.g., depression, schizophrenia, autism, Alzheimer’s Disease, chronic fatigue syndrome) , heart / lung disorders (e.g., chronic obstructive pulmonary disease, congestive heart failure) , metabolic disorders (e.g., obesity, metabolic syndrome, type 1 and 2 diabetes, severe acute pancreatitis) , liver diseases (e.g., alcoholic liver disease, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, liver cirrhosis, primary biliary cholangitis, primary sclerosing cholangitis) , kidney diseases (e.g., renal failure) , microbial infections (e.g., septic shock) , and collagen diseases (e.g., connective tissue disease, scleroderma) .
[0016] The term “inulin” refers to a fructan polysaccharide found in many different types of plants. It is a polymer composed of fructose monomers linked via β- (2-1) -d-frutosyl fructose bonds.
[0017] The term “galactooligosaccharide” or “GOS” is used to refer to an oligosaccharide containing 2-9 molecules of galactose.
[0018] “Polydextrose” is a polysaccharide food ingredient composed of randomly bonded glucose polymers, including about 10%of sorbitol and 1%of citric acid.
[0019] “Tara gum” is obtained by grinding the endosperm of seeds of Caesalpinia spinosa. It is structurally characterized as a galactomannan, and is similar to guar and locust bean gums, two other galactomannans. It consists of a linear chain of (1→4) -β-D-manna pyranose units with α-D-galacto-pyranose units attached by (1→6) linkages with a ratio of mannose to galactose being 3: 1.
[0020] The term "inhibiting" or "inhibition, " as used herein, refers to any detectable negative effect on a target biological process, such as RNA / protein expression of a target gene, the biological activity of a target protein, cellular signal transduction, cell proliferation, presence / level of an organism especially a micro-organism, any measurable biomarker, bio-parameter, or symptom in a subject, and the like. Typically, an inhibition is reflected in a decrease of at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%or greater in the target process (e.g., a subject’s bodyweight, or blood glucose / cholesterol level, or any measurable symptom or biomarker in a subject, such as an infection rate among subjects by a pathogenic infectious agent) , or any one of the downstream parameters mentioned above, when compared to a control. “Inhibition” further includes a 100%reduction, i.e., a complete elimination, prevention, or abolition of a target biological process or signal. The other relative terms such as “suppressing, ” “suppression, ” “reducing, ” and “reduction” are used in a similar fashion in this disclosure to refer to decreases to different levels (e.g., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%or greater decrease compared to a control level) up to complete elimination of a target biological process or signal. On the other hand, terms such as “activate, ” “activating, ” “activation, ” “increase, ” “increasing, ” “promote, ” “promoting, ” “enhance, ” “enhancing, ” or “enhancement” are used in this disclosure to encompass positive changes at different levels (e.g., at least about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, or greater such as 3, 5, 8, 10, 20-fold increase compared to a control level in a target process, signal, or parameter.
[0021] As used herein, the term "treatment" or "treating" includes both therapeutic and preventative measures taken to address the presence of a disease or condition or the risk of developing such disease or condition at a later time. It encompasses therapeutic or preventive measures for alleviating ongoing symptoms, inhibiting or slowing disease progression, delaying onset of symptoms, or eliminating or reducing side-effects caused by such disease or condition. A preventive measure in this context and its variations do not require 100%elimination of the occurrence of an event; rather, they refer to a suppression or reduction in the likelihood or severity of such occurrence or a delay in such occurrence.
[0022] The term “severity” of a disease refers to the level and extent to which a disease progresses to cause detrimental effects on the well-being and health of a patient suffering from the disease, such as short-term and long-term physical, mental, and psychological disability, up to and including death of the patient. Severity of a disease can be reflected in the nature and quantity of the necessary therapeutic and maintenance measures, the time duration required for patient recovery, the extent of possible recovery, the percentage of patient full recovery, the percentage of patients in need of long-term care, and mortality rate.
[0023] A “patient” or “subject” receiving the composition or treatment method of this invention is a human, including both adult and juvenile human, of any age, gender, and ethnic background, who may or may not have been diagnosed with any particular disease or disorder (e.g., may or may not have a diagnosis of a disease involving leaky gut or indicative of compromised gut barrier) but is in need of enhancing gut epithelial barrier function or to reduce risk of developing a disease involving leaky gut or worsening of related symptoms. Typically, the patient or subject receiving treatment according to the method of this invention to improve gut barrier function is not otherwise in need of treatment by the same therapeutic agents. In other words, for a patient to receive a synbiotic composition according to the present invention, the person is not suffering from any condition or disease that is known to be treated by the same composition. In some cases, the subject is not being treated for weight reduction or is not treated for and does not suffer from other metabolic disorders such as obesity, metabolic syndrome including diabetes, especially type 2 diabetes. In some cases, the subject is not being treated for and does not suffer from an ongoing bacterial infection (e.g., a multidrug-resistant bacterial infection) or viral infection such SARS-CoV2 infection or COVID, including its symptoms especially post-acute COVID syndrome (e.g., long COVID, defined as persisting COVID symptoms at least two weeks or at least 3-4 weeks beyond the last positive nucleic acid test) . In some cases, the subject is not treated for improving immunity against an infection (e.g., a viral infection such as COVID) among those at a heightened risk for such infection, especially among children. In some cases, the subject is not treated for enhancing efficacy or safety of vaccination against infection by a pathogen among those who are currently receiving vaccination against a viral infection (e.g., vaccination against COVID) . In some cases, the subject is not being treated for and does not suffer from hair loss, such as due to a disease or treatment thereof (e.g., due to chemotherapy or long COVID or PACS) . In some cases, the subject is not being treated for and does not suffer from eczema or atopic dermatitis. Although a patient may be of any age, in some cases the patient is an adult, or at least 18 years of age. In other cases, the patient is a child under the age of 18 years.
[0024] The term “effective amount, ” as used herein, refers to an amount that produces intended (e.g., therapeutic or prophylactic) effects for which a substance is administered. The effects include the prevention, correction, or inhibition of progression of the symptoms of a particular disease / condition and related complications to any detectable extent, e.g., incidence of disease, infection rate, one or more of the symptoms of a condition or disease involving leaky gut. The exact amount will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992) ; Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999) ; and Pickar, Dosage Calculations (1999) ) .
[0025] The term “about” when used in reference to a given value denotes a range encompassing ±10%of the value.
[0026] A "pharmaceutically acceptable" or "pharmacologically acceptable" excipient is a substance that is not biologically harmful or otherwise undesirable, i.e., the excipient may be administered to an individual along with a bioactive agent without causing any undesirable biological effects. Neither would the excipient interact in a deleterious manner with any of the components of the composition in which it is contained.
[0027] The term "excipient" refers to any essentially accessory substance that may be present in the finished dosage form of the composition of this invention. For example, the term "excipient" includes vehicles, binders, disintegrants, fillers (diluents) , lubricants, glidants (flow enhancers) , compression aids, colors, sweeteners, preservatives, suspending / dispersing agents, film formers / coatings, flavors and printing inks.
[0028] The term “consisting essentially of, ” when used in the context of describing a composition containing an active ingredient or multiple active ingredients, refer to the fact that the composition does not contain other ingredients possessing any similar or relevant biological activity of the active ingredient (s) or capable of enhancing or suppressing the activity, whereas one or more inactive ingredients such as physiological or pharmaceutically acceptable excipients may be present in the composition. For example, a composition consisting essentially of active agents (for instance, a combination of B. adolescentis, B. bifidum, B. longum, and S. thermophilus) effective for enhancing or improving intestinal epithelial barrier function or for treating a disorder involving leaky gut in a subject is a composition that does not contain any other agents that may have any detectable positive or negative effect on the same target process (e.g., gut barrier function or a leaky gut condition such as inflammatory bowel disease) or that may increase or decrease to any measurable extent of the disease severity among the receiving subjects.DETAILED DESCRIPTION OF THE INVENTION
[0029] I. Introduction
[0030] The gut epithelium is constituted of a single layer of different intestinal epithelial cells. Together with the junctions that seal the paracellular space between epithelial cells such as tight junction, it contributes to the epithelial barrier function which could limit interactions between luminal contents such as the gut microbiota and the underlying immune system, while supporting transport of nutrients, water and waste products1. On the other hand, disruption of the epithelial barrier increases intestinal permeability, resulting in leaky gut syndrome (LGS) 2. This may lead to pathogen translocation and promote endotoxemia3. In genetically susceptibly individuals, leaky gut may allow environmental factors entering the body and trigger the development of autoimmune disease4. The gut microbiome, having strong interaction with the gut epithelium, regulate the integrity and function of the intestinal barrier. A perturbed gut microbiota may disrupt the intestinal barrier while certain beneficial microorganisms may help restore it. It was unclear, however, which specific microorganisms have such effect. This disclosure reveals pertinent information for the first time and offers novel compositions and methods to restore the gut epithelial barrier.
[0031] This invention describes a specific combination of bacteria (Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus) , optionally in further combination with certain prebiotics (e.g., inulin, galactooligosaccharide, polydextrose, and optionally tara gum) , for enhancing intestinal epithelial barrier function or for treating / preventing a disease or disorder involving leaky gut in a subject. The practical use of the invention includes development and manufacturing of commercial food products or health supplements, for example in the form of a powder, tablet, capsule, or liquid, which can be taken alone or added to food or beverages.
[0032] II. Pharmaceutical Compositions and Administration
[0033] The present invention provides pharmaceutical compositions comprising an effective amount of B. adolescentis, B. bifidum, B. longum, and S. thermophilus, optionally in further combination with inulin, galactooligosaccharide, polydextrose, and tara gum for enhancing gut epithelial barrier function in a person to reduce the risk of a disease involving compromised gut barrier, or for treating related conditions and symptoms. Pharmaceutical compositions of the invention are suitable for use in a variety of drug delivery systems. Suitable formulations for use in the present invention are found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA, 17th ed. (1985) . For a brief review of methods for drug delivery, see, Langer, Science 249: 1527-1533 (1990) .
[0034] The pharmaceutical compositions of the present invention can be administered by various routes, e.g., systemic administration via oral ingestion or local delivery using a rectal suppository. The preferred route of administering the pharmaceutical compositions is oral administration at daily doses of about 106 to about 1012 CFU for the combination of Bifidobacteria adolescentis, Bifidobacteria bifidum, Bifidobacteria longum, and Streptococcus thermophilus at a CFU ratio of about (1-2) : about 1: about (0.5-1.5) : about (0-2) ; or about 1: about 1: about 1: about 1; or about 2: about 1: about 1.5: about 2; or about 1: about 1: about 0.5: about 0 (not present or not detectable) ; or about 1.5: about 1: about 1.5: about 1; or about 1: about 1: about 1: about 0 (not present or not detectable) . In some cases, one or more of the Bifidobacteria adolescentis, Bifidobacteria bifidum, Bifidobacteria longum, and Streptococcus thermophilus consist of one or more strains from the same species.
[0035] In some cases, the synbiotic composition of this invention consists essentially of the beneficial bacteria species (Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus) , excluding other bacterial species at any detectable level (e.g., detection by a polymerase chain reaction-based methodology) , for example, one or more of Faecalibacterium prausnitzi, Eubacterium halli, Roseburia intestinalis, Eubacterium eligens, Lachnospiraceae bacterium_5_1_63FAA, Eubacterium ventriosum, Roseburia hominis, Bifidobacteria breve, Bifidobacteria infantis, Bifidobacterium pseudocatenulatum, Blautia wexlerae, and Fusicatenibacter saccharivorans.
[0036] In some cases, the prebiotic combination of inulin, galactooligosaccharide, polydextrose, and optionally further with tara gum is also administered to the subject, either in one single composition or in multiple compositions. Typically, the ingredients of inulin, galactooligosaccharide, and polydextrose are present in the composition in the weight ratio of about (2-5) : about 1: about (2-4) . Optionally, tara gum is also included, with inulin, galactooligosaccharide, polydextrose, and tara gum present in the composition in the weight ratio of about (2-5) : about 1: about (2-4) : about (0-0.5) . For example, the combination of inulin, galactooligosaccharide, and polydextrose, optionally with tara gum, may be present in total amount of about 0.1 to about 10 grams, e.g., about 0.5 to about 6 grams, about 1 to about 4 grams, or about 1.2 to about 1.5 grams, with higher levels more suitable for use in combination with food especially when mixed in a food item. In some cases, the composition is formulated in the form of a food or beverage item, for example, in a daily dosage of inulin, galactooligosaccharide, polydextrose, and tara gum in the amount of about 0.1 to about 8 grams.
[0037] Additionally, the composition may be formulated in a daily dosage format in the total amount of about 0.01 to about 50 mg / kg, about 0.1 to about 25 mg / kg, about 1 to about 20 mg / kg, or about 2 to about 10 mg / kg of a subject who is to receive the composition. The appropriate dose may be administered in a single daily dose or as divided doses presented at appropriate intervals, for example as two, three, four, or more subdoses per day. The duration of administration may range from about 2 weeks to about 4 weeks, or from about 1 or 2 months to about 6 or 12 months, e.g., from about 1 week to about 4 weeks, or from about 1 month to about half to one year, following the onset or worsening of symptoms of a condition involving leaky gut or indicative of a compromised gut epithelial barrier function. In essence, the composition of this invention may be administered to a subject in need thereof for as long as any one of the pertinent condition exists. The composition may also be administered indefinitely for the long-term maintenance of a healthy gut epithelial barrier.
[0038] For preparing pharmaceutical compositions containing the beneficial bacteria combination optionally with the prebiotics combination, one or more inert and pharmaceutically acceptable carriers are used. The pharmaceutical carrier can be either solid or liquid. Solid form preparations include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories. A solid carrier can be one or more substances that can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
[0039] In powders, the carrier is generally a finely divided solid that is in a mixture with the finely divided active component, e.g., the combination of B. adolescentis, B. bifidum, B. longum, and S. thermophilus, optionally further in combination of one or more of inulin, galactooligosaccharide, and polydextrose, optionally with tara gum. In tablets, the active ingredient is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
[0040] For preparing pharmaceutical compositions in the form of suppositories, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient-sized molds and allowed to cool and solidify.
[0041] Powders and tablets preferably contain between about 5%to about 100%by weight of the active ingredient (s) (e.g., the beneficial bacteria combination of B. adolescentis, B. bifidum, B. longum, and S. thermophilus, optionally further in combination with one or more of inulin, galactooligosaccharide, and polydextrose, optionally with tara gum) . Suitable carriers include, for example, magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.
[0042] The pharmaceutical compositions can include the formulation of the active ingredient (s) e.g., the combination of B. adolescentis, B. bifidum, B. longum, and S. thermophilus, optionally further in combination with inulin, galactooligosaccharide, and polydextrose, optionally with tara gum, with encapsulating material as a carrier providing a capsule in which the active ingredient (s) (with or without other carriers) is surrounded by the carrier, such that the carrier is thus in association with the active ingredient (s) . In a similar manner, sachets can also be included. Tablets, powders, sachets, and capsules can be used as solid dosage forms suitable for oral administration.
[0043] Liquid pharmaceutical compositions include, for example, solutions suitable for oral administration or local delivery, suspensions, and emulsions suitable for oral administration. Sterile water solutions of the active component (e.g., B. adolescentis, B. bifidum, B. longum, and S. thermophilus, optionally further in combination with inulin, galactooligosaccharide, and polydextrose, optionally with tara gum) or sterile solutions of the active component in solvents comprising water, buffered water, saline, PBS, ethanol, or propylene glycol are examples of liquid or semi-liquid compositions suitable for oral administration or local delivery such as by rectal suppository. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, detergents, and the like.
[0044] Sterile solutions can be prepared by dissolving the active component (e.g., the combination of B. adolescentis, B. bifidum, B. longum, and S. thermophilus, optionally further in combination with inulin, galactooligosaccharide, and polydextrose, optionally with tara gum) in the desired solvent system that has been previously sterilized under sterile conditions. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the preparations typically will be between 3 and 11, more preferably from 5 to 9, and most preferably from 7 to 8.
[0045] Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician or nutritionist. In any event, the pharmaceutical formulations should provide a quantity of active agents sufficient to effectively enhance the function of intestinal epithelial barrier in a recipient and / or reduce or eliminate symptoms or effects of a condition involving leaky gut or indicative of compromised gut epithelial barrier.
[0046] The practical use of the invention includes development and manufacturing of commercial food products or health supplements, for example in the form of a powder, tablet, capsule, or liquid, which can be taken alone or added to food or beverages, especially in connection with other efforts to maintain healthy gut epithelial barrier at or around the same time.
[0047] III. Kits
[0048] The invention also provides kits for improving gut barrier function in an individual (e.g., for preventing or treating a condition or disorder involving leaky gut) according to the method disclosed herein. The kits typically include a plurality of containers, each containing a composition comprising beneficial bacteria B. adolescentis, B. bifidum, B. longum, and S. thermophilus. Optionally, additional container (s) may be included in the kit providing composition (s) comprising one or more of prebiotics selected from galactooligosaccharide, inulin, and polydextrose, and tara gum. Further, additional agents or drugs that are known to be therapeutically effective for prevention and / or treatment of the condition or disorder, including for ameliorating the symptoms and reducing the severity of the disease, as well as for facilitating recovery from the disease may be included in the kit. The plurality of containers of the kit each may contain a different active agent or a distinct combination of two or more of the active agents. The kit may further include informational material providing instructions on how to dispense the pharmaceutical composition (s) , including description of the type of patients who may be treated (e.g., human patients who have been deemed as with high risk of developing a condition or disorder involving compromised gut barrier function, but have not received a diagnosis of such condition or disorder, or human patients who have been diagnosed with such a condition or disorder) and are therefore seeking to improve or enhance gut barrier function or to reduce the symptoms or severity of the condition or disorder. Furthermore, the instructions may identify the type of patients to be excluded from receiving the claimed treatment method (e.g., those who have been diagnosed with a pre-existing condition that already requires administration of the same active components) . Information such as the dosage, frequency, and manner of administration of the compositions provided in the kit is also provided.
[0049] EXAMPLES
[0050] The following examples are provided by way of illustration only and not by way of limitation. Those of skill in the art will readily recognize a variety of non-critical parameters that could be changed or modified to yield essentially the same or similar results.
[0051] EXAMPLE I
[0052] Formula and Suggested Dose of SMT04
[0053] SMT04 comprises primarily four probiotic bacteria species, and in addition, prebiotics that promote the growth of these probiotic bacteria in the gut. The prebiotics are optional.
[0054] Bifidobacterium adolescentis (Ba) , Bifidobacterium bifidum (Bb) , Bifidobacterium longum (Bl) , and Streptococcus thermophilus (St) are selected due to their high relative abundance and prevalence in healthy individuals. The ratio of each bacteria species in the synbiotic composition is listed, for example, in Table 1. The composition may comprise at least 1.0x106 CFU of all bacteria species combined, e.g., between 1.0x106 and 9.0x1012 CFU per daily use. For each bacteria species in SMT04, one or more strains of that species may be present.
[0055] Table 1 Ratio of bacteria species in the synbiotic composition (SMT04)
[0056] CFU: colony forming unit
[0057] Prebiotics are non-digestible polysaccharides and oligosaccharides, which are fermented selectively by beneficial bacteria in the colon and can promote their growth. They are beneficial for the growth of the probiotic microorganism and help to provide a favorable environment for the probiotic microorganism to survive during transit in the gastrointestinal tract, so to improve their delivery to the gut. The synbiotic composition of this invention may contain one or more prebiotics including inulin, galactooligosaccharide (GOS) , polydextrose, and tara gum. In some cases, the four prebiotics, inulin, galactooligosaccharide (GOS) , polydextrose, and tara gum are included at an approximate weight ratio of (2-5) : 1: (2-4) : (0-0.5) . The total amount of prebiotics to be added to the composition may be from 0.1 to 8g per day, for example, from 1.2g to 4g per day.
[0058] The suggested daily dose of SMT04 is shown in Table 2.
[0059] Table 2 Suggested amount per daily dose
[0060] CFU: colony forming unit
[0061] Example II -Synbiotic Composition (SMT04) Improved Gut Barrier Function
[0062] METHOD
[0063] Bacteria culture
[0064] Bifidobacterium adolescentis (Ba) , Bifidobacterium bifidum (Bb) , Bifidobacterium longum (Bl) , and 2 strains of Streptococcus thermophilus (St) were cultivated separately in brain heart infusion broth (BHI, Oxoid, Thermo Fisher Scientific, USA) overnight at 37 ℃ in hungate tubes filling with 100%CO2. After overnight culture, Ba, Bb, Bl, and St (2 strains) that make up the probiotic component of SMT04, were mixed at the ratio of (1-2) : 1 (0.5-1) : (0.5-1) .
[0065] Cell culture and monolayer preparation
[0066] Human epithelial cell line Caco-2, which were widely used as model to mimic intestinal permeability, were bought from ATCC (American Type Culture Collection, Manassas, VA, USA) and preserved in the lab. Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco, Thermo Fisher Scientific, USA) supplied with 10%fetal bovine serum (FBS, Gibco, Thermo Fisher Scientific, USA) in cell culture incubator at 37℃and 5%CO2. The Caco-2 cells were seeded on 24 well 12 mm polyester Transwell filters (Corning, Corning, NY, USA) with 0.4 μM pore size at a concentration of 2.5 × 105 cells per well and grown as a monolayer.
[0067] Lipopolysaccharide (LPS) induced gut barrier dysfunction
[0068] Lipopolysaccharides from E. coli (LPS) was bought from Thermo Fisher Scientific to establish an endotoxin induced epithelial tight junction dysfunction. For treatment, cells were stimulated with 100 ng / mL LPS with or without probiotic treatment for 24 hours. After the 24-hour incubation, cells were collected for total RNA isolation and tight junction protein gene expression analysis by the real-time PCR method. All other solutions and equipment that were in contact with the cells had been autoclaved before use. Cells were handled in a biosafety cabinet.
[0069] Quantification of tight junction protein gene and pro-inflammatory expression using real-time PCR
[0070] Total RNA was isolated from the treated cells with TRIzol reagent (TAKARA, Japan) following the manufacturer's instructions. RNA was quantified and qualified with the NanoDrop One spectrophotometer (Thermo Fisher Scientific, USA) . Equal amounts of total RNA (0.5 μg) from each sample were reverse transcribed to cDNA with PrimeScriptTMRT Master Mix (TAKARA, Japan) , following the manufacturer's protocol.
[0071] Real-time PCR was performed in a final volume of 10 μL including 2uL sample cDNA with TB Premix Ex Taq (TAKARA, Japan) . The reaction mixtures were incubated for an initial denaturation at 94 ℃ for 5 min, followed by 40 PCR cycles: 40 s at 95 ℃, 30 s at 60 ℃ and 30 s at 72 ℃ with QuantStudioTM 7 Flex Real-Time PCR System (Thermo Fisher Scientific, USA) .
[0072] FITC-dextran permeability assay
[0073] In vitro permeability was determined by measuring the flow of fluorescein isothiocyanate (FITC) -dextran across the Caco-2 monolayer cell culture. FITC-dextran with a molecular weight of 4 kDa was added to the upper chamber at the concentration of 3mg / mL without medium change. Aliquots of media were collected from the lower chambers after 4 hours of incubation. The fluorescence intensity was detected at 515 nm.
[0074] RESULTS AND DISCUSSION
[0075] SMT04 suppressed inflammatory cytokine
[0076] Lipopolysaccharide (LPS) is a gut-transmitted endotoxin from Gram-negative bacteria. It could cause inflammation by triggering the inflammatory signal cascades and activating inflammatory mediators including interleukin-6 (IL-6) , which could lead to the loss of gut barrier function through tight junction protein injury, and eventually increase gut permeability. To evaluate the protective role of SMT04 in protecting the gut barrier function, we challenged a model of human gut epithelium, the Caco-2 cell monolayers, with LPS to induce gut barrier impairment.
[0077] IL-6 is a key cytokine of the acute inflammatory response. Uncontrolled IL-6 expression leads to profound inflammatory damage to host cells 5. Level of IL-6 was evaluated as an indicator of inflammatory response. The ability of bacteria or bacterial components to induce IL-6 in high intensity and chronicity can be regarded as an aspect of bacterial virulence. To evaluate safety of SMT04, conditioned culture medium of SMT04 (i.e., the supernatant of bacteria culture) was collected from the overnight culture of SMT04 (see method for detail) , and was used to challenge Caco-2 cells. As shown in FIG. 1A, treatment with SMT04 conditioned culture medium for 24 hours did not result in any increase of IL-6 secretion. The effect of SMT04 on LPS-induced inflammation was next evaluated in Caco-2 cells. LPS treatment alone significantly increased the expression of IL-6 expression, while simultaneous treatment of LPS with SMT04 significantly reduced level of IL-6 induced by LPS to the level that has no significant difference from blank control (FIG. 1B) .
[0078] SMT04 preserved gut epithelial barrier function by regulating tight junction protein
[0079] Tight junction is one of the intercellular junctions at the level of the epithelial cells, where occludin (OCLN) , zonula occludens 1 (ZO1) , and claudin 1 are key components. To investigate the effects of SMT04 on gut epithelial barrier function, Caco-2 cells were seeded onto Transwell insert and were cultured for 2 weeks to establish a monolayer. Cells were then treated with LPS for 24 hours to induce acute gut epithelial barrier dysfunction. Simultaneously, cells were treated with or without SMT04. Cells without any treatment of LPS or SMT04 were used as blank control. LPS caused a significant decrease in the expression of tight junction proteins OCLN (FIG. 2A) and claudin 1 (FIG. 2C) , while simultaneous treatment of SMT04 fully or partially restored the expression of such proteins. Although the decrease in the expression ZO-1 induced by LPS was not significant compared to blank control, simultaneous treatment of SMT04 reinstated the expression of ZO-1 to a level significantly higher than that of LPS only treatment (FIG. 2B) .
[0080] SMT04 improved gut permeability
[0081] FITC-dextran permeability assay was performed to investigate effect of SMT04 on gut permeability. The permeability assay measures the fluorescence intensity of FITC-dextran permeating through the monolayer-cultured cells on the Transwell. A higher FITC intensity in the lower chamber indicates higher permeability. Caco-2 Transwell monolayer cultures (prepared as described above) were treated with LPS for 24 hours to mimic the condition of increased gut permeability. Simultaneously, these cultures were treated with or without SMT04 to evaluate SMT04’s protective effect. Cells without any treatment were used as black control. The effect of treatment with SMT04 alone was also evaluated. FITC-dextran permeability assay confirmed that LPS treatment significantly increased gut permeability. SMT04 improved gut permeability under LPS treatment to the level similar to blank control. Treatment with SMT04 alone showed no effect on gut permeability (FIG. 3) .
[0082] All patents, patent applications, and other publications, including GenBank Accession Numbers and equivalents, cited in this application are incorporated by reference in the entirety for all purposes.
[0083] List of references
[0084] 1. Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol 2017; 14: 9-21.
[0085] 2. Kinashi Y, Hase K. Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity. Front Immunol 2021; 12: 673708.
[0086] 3. Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut 2019; 68: 1516-1526.
[0087] 4. Mu Q, Kirby J, Reilly CM, et al. Leaky Gut As a Danger Signal for Autoimmune Diseases. Front Immunol 2017; 8: 598.
[0088] 5. Luo Y, Zheng SG. Hall of Fame among Pro-inflammatory Cytokines: Interleukin-6 Gene and Its Transcriptional Regulation Mechanisms. Front Immunol 2016; 7: 604.
Claims
1.A composition for use in enhancing or restoring gut epithelial barrier in a subject comprising an effective amount of (1) Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus; and (2) a physiologically acceptable excipient.2.The composition of claim 1, wherein Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus are present in the composition in the colony-forming unit (CFU) ratio of about (1-2) : about 1 : about (0.5-1.5) : about (0-2) .3.The composition of claim 1 or 2, comprising one or more strains of each of Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus.4.The composition of any one of claims 1-3, comprising a total of about 106 to about 1012 CFU of Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus.5.The composition of any one of claims 1-4, further comprising inulin, galactooligosaccharide, and polydextrose.6.The composition of claim 5, wherein inulin, galactooligosaccharide, and polydextrose are present in the composition in the weight ratio of about (2-5) : about 1 : about (2-4) .7.The composition of any one of claims 1-6, further comprising tara gum.8.The composition of claim 7, wherein inulin, galactooligosaccharide, polydextrose, and tara gum are present in the composition in the weight ratio of about (2-5) : about 1 : about (2-4) : about (0-0.5) .9.The composition of claim 7, comprising a total amount of about 0.1 to about 8 grams of inulin, galactooligosaccharide, polydextrose, and tara gum.10.The composition of any one of claims 1-9, which is formulated for oral ingestion.11.The composition of any one of claims 1-10, which is in the form of a food or beverage item.12.The composition of any one of claims 1-11, which is formulated in subdoses for administration two, three, four, or more times per day with one subdose each time.13.A method for enhancing or restoring gut epithelial barrier function in a subject in need thereof, comprising administering to the subject an effective amount of the composition of any one of claims 1-12.14.The method of claim 13, wherein the administering step comprises administering to the subject one composition comprising Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus.15.The method of claim 13 or 14, wherein the subject is administered inulin, galactooligosaccharide, and polydextrose, optionally further administered tara gum.16.The method of claim 19, wherein the administering step comprises administering to the subject a first composition comprising Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus, and administering to the subject a second composition comprising inulin, galactooligosaccharide, polydextrose, and tara gum.17.The method of any one of claims 13-16, wherein the administering step comprises oral ingestion of the composition (s) .18.The method of claim 17, wherein the administering step comprises oral ingestion prior to or with food intake.19.The method of any one of claims 13-18, wherein the subject has been diagnosed with an intestinal disease or is at risk for an intestinal disease.20.A kit for enhancing or restoring gut epithelial barrier function in a subject in need thereof, comprising a plurality of compositions together comprising an effective amount of Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus, optionally further comprising an effective amount of inulin, galactooligosaccharide, polydextrose, and tara gum.21.The kit of claim 20, comprising two compositions, wherein the first composition comprises an effective amount of Bifidobacterium adolescentis, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus, and wherein the second composition comprises an effective amount of inulin, galactooligosaccharide, polydextrose, and tara gum.22.The kit of claim 20 or 21, wherein the compositions are in the form of a powder, liquid, paste, cream, tablet, or capsule.
